ITF shared a community letter and presented new data, including long-term safety observations based on data from the company’s ongoing open-label extension study in patients with Duchenne muscular dystrophy treated with givinostat. In addition, analyses from the givinostat clinical development program include findings on reduction of decline in muscle contractile area and potential delay in median age at loss of ambulation.
Read the community letter:
The post ITF Therapeutics Shares Community Letter and Presents New Data and Analyses on DUVYZAT® (givinostat) appeared first on CureDuchenne.